We describe DriverPower, a software package that uses mutational burden and functional impact evidence to 2 identify cancer driver mutations in coding and non-coding sites within cancer whole genomes. Using a total of 3 1,373 genomic features derived from public sources, DriverPower's background mutation model explains up to 4 93% of the regional variance in the mutation rate across a variety of tumour types. By incorporating functional 5 impact scores, we are able to further increase the accuracy of driver discovery. Testing across a collection of 2,583 6 cancer genomes from the Pan-Cancer Analysis of Whole Genomes (PCAWG) project, DriverPower identifies 217 7 coding and 95 non-coding driver candidates. Comparing to six published methods used by the PCAWG Drivers 8 and Functional Interpretation Group, DriverPower has the highest F1-score for both coding and non-coding driver 9 discovery. This demonstrates that DriverPower is an effective framework for computational driver discovery.
Introduction 11
Cancer drivers are somatic genetic alterations that confer selective advantages to tumour cells 1, 2 . 12
Identification of cancer drivers is a crucial yet challenging task in cancer genomics research 3, 4 . 13
There are multiple challenges. First, driver mutations generally account for only a small fraction 14 of the somatic variations found in a typical tumour, the rest being innocent bystander "passenger" 15 mutations 5 . Second, there is substantial intra-and inter-tumoural heterogeneity in most cancers 6 . 16
Both across different tumour types and across different genomic regions within the same tumour, 17
the background mutation rate can vary over several orders of magnitude. 18
The advent of large scale cancer whole-genome sequencing (WGS) data, such as the˜2,600 19 tumour and matched normal whole genomes from the ICGC/TCGA Pan-Cancer Analysis of Whole 20
Genomes (PCAWG) project, has made it possible to explore the role of driver events in non-21 coding regions. However, identifying non-coding driver events in WGS creates new challenges. 22
First, while the functional impact of somatic mutations in the coding regions of genes is fairly 23 straightforward to predict, much less is known about the effect of mutations on non-coding 24 regions of the genome. Second, only˜1% of somatic mutations detected in PCAWG WGS data 25 are exonic, adding substantially more mutations and regions to be tested and demanding more 26 careful control of type I and type II errors than whole exome sequencing. At present, only a limited 27 number of non-coding drivers are known, the primary examples being the TERT promoter for 28 multiple tumour types and the TAL1 enhancer for T cell acute lymphoblastic leukaemia 7, 8 . 29
Most state-of-the-art methods identify drivers by detecting signals of positive selection either 30 through mutational burden tests, which compare the rate of mutations observed in a region of 31
the genome to what is expected from the background mutation rate, or functional impact tests, 32
which identify putative driver mutations based on a higher-than-expected rate of changes that 33 are predicted to alter the function of genomic elements 3,6 . Mutational burden tests work best for 34 calling frequently recurrent driver events and perform poorly when applied to rare driver events.
35
In contrast, functional impact tests fail to find drivers in genomic elements that are poorly 36 understood or annotated. To maximize accuracy, we combined the two mutation significance 37 testing methods to develop DriverPower (Fig. 1a) , a framework for identification of coding and 38 non-coding cancer drivers using mutational burden and functional impact scores. 39
Results

40
To evaluate DriverPower, we took WGS somatic variant data derived from 2,583 high-quality 41 donors from the PCAWG project 9 . After removing hypermutated samples, 2,514 donors with 42 24,715,214 somatic single nucleotide variants (SNV) and small indels were used for driver element 43
identification. We analysed this data both as a single pan-cancer data set, as well as a series of 44 29 tumour type-specific cohorts ( Supplementary Table 1 ). 45
Features predictive of background mutation rate 46 Among all tumour cohorts, we observed substantial variability in the observed mutation rate at 47 the tissue, donor and locus levels ( Supplementary Fig. 1 and 2). Accurate driver detection re-48
quires an accurate estimate of background mutation rate across the tumour genome, taking into 49 account the extensive variability among tumour types, donors and genomic regions. DriverPower 50 tackles this issue by modelling the background mutation rate (BMR) using numerous genomic 51
features that co-vary with the localized background mutation rate. We collected 1,373 fea-52
tures from three public data portals ( Supplementary Table 2 ): the ROADMAP Epigenomics 53 project, the ENCODE project and the UCSC genome browser 10,11,12 . These features covered 54 seven main categories: conservation, DNA accessibility, epigenomic marks, nucleotide contents, 55
replication timing, RNA expression and genome compartments. As expected, we found extensive 56 multicollinearity among features. Most features (1368/1373) are significantly correlated with 57
pan-cancer genome-wide mutation rates (Spearman's rho test q<0.1; Supplementary Fig. 3) . 58 Background mutation rate model 59 We investigated two algorithms for modelling the BMR based on genomic features. The first algo-60 rithm was randomized lasso followed by binomial generalized linear model (GLM). The alternative 61 algorithm was the gradient boosting machine (GBM), which is a non-linear and non-parametric 62 tree ensemble algorithm 13 . To evaluate both BMR modelling algorithms, we made non-overlapped 63 1 megabase pair (Mbp) autosomal elements (n=2,521) as well as training genomic elements 64 (n=867,266) by sampling genomic coordinates randomly. The number of mutations per element 65 was then predicted with 5-fold cross-validation. 66
When evaluated using 1Mbp autosomal elements, we found that both algorithms could accurately 67 predict the background mutation rate ( Supplementary Fig. 4 and 5). In high mutational 68
burden tumour cohorts, we observed essentially no difference between two algorithms, however 69 GBM consistently outperformed GLM when applied to low mutational burden tumour cohorts 70
( Supplementary Fig. 6 ). When evaluated on the training element set, in which the size of 71 element varies from 100 bp to 1 Mbp, the prediction accuracy drops due to higher BMR variability, 72 especially for low mutational burden tumour cohorts such as Myeloid-MPN and CNS-PiloAstro 73
( Supplementary Fig. 6 ). However, for large cohort such as the pan-cancer set (N=2,253), 74
around 93% of the mutation rate variance on the training set is explained by either model (Fig.  75 1b). The model still shows excellent performance when applied to the test element set, explaining 76
83% of the mutation rate variance on the pan-cancer cohort (Fig. 1c) . 77
Both the randomized lasso algorithm and the GBM can be used to rank feature importance in 78 different ways. Feature selection ranking from both methods confirmed that H3K9me3 (associ-79 ated with heterochromatin), replication timing and H3K27ac (or its antagonistic histone mark 80
H3K27me3) are the most important groups of predictors for BMR ( Supplementary Fig. 7  81 and Supplementary Table 2 ) 14 . Consistent with previous results, we found that features from 82 tumour cell lines with similar cell-of-origin to the primary tumour type are frequently selected 15 . 83
For example, replication timing from liver cancer cell line HepG2 was selected as a feature for the 84 BMR in hepatocellular carcinoma (Liver-HCC), while replication timing in MCF7 (breast cancer) 85
and SK-N-SH (neuroblastoma) were selected for breast adenocarcinoma (Breast-AdenoCA) and 86 glioblastoma (CNS-GBM), respectively ( Supplementary Fig. 8 ). 87
Functional adjustment 88
In most burden-based methods mutations are equally weighted. However, not all mutations 89
have the same functional consequences. To incorporate functional consequence information, 90
DriverPower implements a posterior functional adjustment. The functional adjustment step up-91 weights mutations with high predicted functional impact. While the DriverPower framework can 92 potentially work with any functional scoring scheme, in the current implementation we measured 93 the functional impact using four published scoring schemes: the CADD 16 , DANN 17 , EIGEN 18 and 94 LINSIGHT 19 scores. Although different training data, assumptions and algorithms are used by 95 different scores, we found those scores to be consistent at the element level (Supplementary 96 Fig. 9 ). We used the average weight of all four scores in the remainder of the manuscript unless 97 otherwise specified. 98
Candidate driver event discovery 99
To evaluate the DriverPower algorithm, we first employed three simulated variant sets generated 100 by the PCAWG Drivers and Functional Interpretation Group (PDFIG) to examine type I and type 101 II errors. We expected to identify no drivers as all three simulated datasets are reshuffles of 102 observed mutations. In general, we observed no inflation or deflation in simulations and only 8 103 significant hits were identified in˜11M statistical tests ( Supplementary Fig. 10 When compared to six other methods using the same 26 non-melanoma/lymphoma cohorts and 138 CGC as the gold standard set, DriverPower (precision=0.84; recall=0.79) had the highest F1-139 score (0.81) ( Fig. 2b, c) . In our benchmark, sensitivity was a bottleneck for most methods (4/7 140 with recall<0.5). When compared to the method with highest recall, the widely used coding 141 driver caller MutSig (precision=0.80; recall=0.80), DriverPower identified an additional 21 genes 142 present in CGC (23 for MutSig; Supplementary Fig. 12 ). 143
We next benchmarked DriverPower's accuracy for non-coding driver events. For the prediction 144 of driver events affecting the splice sites of coding genes, DriverPower called 47 significant can-145 didates with 85.1% (40/47) within CGC. DriverPower (F1=0.91) also outperformed two recently 146 published methods, ncdDetect (F1=0.65) and oncoDriverFML (F1=0.32), for splice site driver 147 detection ( Supplementary Fig. 13 ). 148
For the prediction of non-coding driver events in 3'UTRs, 5'UTRs, promoters and enhancers, 149
DriverPower identified 19 candidates in non-melanoma/lymphoma tumour cohorts and 24 can-150
didates in the pan-cancer cohort. Benchmarking results showed that DriverPower has the high-151
est F1-score (0.79) among the six methods evaluated ( Fig. 2d, For long non-coding RNA (lncRNA) genes and their promoters, DriverPower found 9 candidates 162 in total. Among them, 6 and 3 were contained within PCAWG-consensus and PCAWG-raw, 163
respectively. These candidates targeted three unique lncRNAs: RN7SK, RMRP and RPPH1. 164
The promoter of RMRP was significantly mutated in four cohorts (Breast-AdenoCA, Liver-HCC, 165
Stomach-AdenoCA and pan-cancer) and has been nominated as a novel non-coding driver. 166
DriverPower-exclusive driver candidates overview 167 A total of 11 coding and 17 unique non-coding candidates were exclusively identified by Driver-168
Power (not present in either CGC or PCAWG-consensus; Supplementary Table 4 ). We sought 169
to evaluate these exclusive driver candidates using literature evidence and correlative orthogonal 170
data such as the effect of the variant on RNA-seq expression levels and the presence of somatic 171 copy number alterations (SCNAs) and somatic structural variations (SVs) covering the same re-172 gions. On this basis, we found that many of the DriverPower-exclusive candidates are plausible 173 cancer drivers. 174
Among protein coding genes, DriverPower identified EEF1A2 (eukaryotic translation elongation 175 factor 1 alpha 2) in the esophageal adenocarcinoma cohort (Eso-AdenoCA; 7/95 samples). All 176 seven observed mutations were missense ( Supplementary Fig. 14a ). Although no RNA-seq 177
data is available for Eso-AdenoCA samples, SCNA analysis indicated that EEF1A2 is amplified in 178 69.5% (66/95) of Eso-AdenoCA samples (vs. 27.9% of non-Eso-AdenoCA samples; Supplemen-179 tary Fig. 14b ), suggesting a potential gain-of-function role in this cancer type. The amplification 180 of EEF1A2 (20q13.33) was also confirmed by the GISTIC2.0 (q=0.0006). for Lymph-BNHL ( Supplementary Fig. 14e ), resulting in a total of 13.3% (14/105) Lymph-195 BNHL samples being affected by non-synonymous or splice site mutations in SGK1. SGK1 is 196 present in PCAWG-raw but was filtered out due to the large number of AID-related variants in 197 this tumour cohort. However, differential expression analysis indicated that SGK1 is significantly 198 overexpressed in mutated Lymph-BNHL samples relative to non-mutated samples (copy number 199 corrected p=3e-13; Fig. 2f ). SGK1 encodes a serine/threonine protein kinase that plays an im-200 portant role in cellular stress response and its CDS has been nominated as a driver in earlier WES 201 studies 35, 36 . Another study has also demonstrated that the administration of an SGK1 inhibitor 202
induces apoptosis in lymphoma cell lines 38 . Together these data support a potential driver role 203
for SGK1 in Lymph-BNHL. 204
The GPR126 (adhesion G protein-coupled receptor G6) enhancer candidate was filtered out 205 from the PCAWG-raw set because of mutations in palindrome loops, which makes it unclear 206
whether mutations in the GPR126 enhancer are caused by mutational mechanism associated 207 with palindrome loops or positive selection. We found that the GPR126 enhancer is recurrently 208 mutated in transitional cell carcinoma of the bladder (Bladder-TCC; 14/23 samples) and breast 209 adenocarcinoma (Breast-AdenoCA; 8/195) ( Supplementary Fig. 14f ). GPR126 is among 210
the MammaPrint® 70 gene panel used to predict the risk of breast cancer metastasis 39, 40 . A 211 study also shows that knockdown of GPR126 can inhibit the hypoxia-induced angiogenesis in 212 model organisms 41 . Differential expression analysis demonstrated that the GPR126 is signifi-213
cantly downregulated in Bladder-TCC samples with enhancer mutations (copy number corrected 214 p=0.012; Fig. 2g ) relative to those carrying the wild type enhancer, suggesting a functional role 215 for these mutations. 216
Several somatically altered histone genes have been implicated in human cancer, such as H3F3A 217
(identified as a pan-cancer driver in this study), H3F3B and HIST1H3B to-mesenchymal transition 52 . The 5'UTR and promoter of SRSF9 (serine and arginine rich splicing 236 factor 9) was significant in DriverPower's results for pan-cancer and not present in any reference 237 driver sets. The protein encoded by SRSF9 is part of the spliceosome; a previous study indicates 238 that the proto-oncogene SRSF9 is overexpressed in multiple tumours and that this overexpressi-239 on can cause the accumulation of β-Catenin 53 . The same study also showed that the depletion 240 of SRSF9 proteins could inhibit colon cancer cell proliferation. 241
In summary, 4/11 coding and 4/17 unique non-coding driver candidates exclusively called by 242
DriverPower had some form of support from the literature or orthogonal evidence. If we assume 243 that all the exclusive candidates that lack such evidence are false positives, then this puts an 244 estimate of DriverPower's false discovery rate across the PCAWG data set at 3.2% (7/217) 245
for coding and 16.8% (16/95) for non-coding regions. However, this assumption is probably 246
invalid as most of these lack-of-evidence candidates are also identified by other methods and 247 present in PCAWG-raw. We acknowledge that lack-of-evidence candidates may contain false 248 positive calls, but they may also contain previously unknown drivers. For example, the 5'UTR 249
of TBC1D12 in Breast-AdenoCA, which has been filtered out from the PCAWG-raw due to 250 possible hypermutability, is called by all but one driver discovery methods and is reported as 251 a putative cancer driver in previous studies because of two recurrent mutations in the Kozak 252 consensus sequence involving in the initiation of protein translation 23,54 . Moreover, according to 253
another recent study, the same TBC1D12 candidate is still statistically significant in breast cancer 254 even after removing hypermutations, but whether these mutations can alter protein translation 255 in cancer is still undetermined 24 . Some lack-of-evidence candidates may also fit the mini-driver 256 model of cancer evolution 55 . Unlike classical drivers, mini-drivers can only weakly promote and 257
are not essential for tumour progression, hence present at a lower frequency in cancer cohorts. 258
Further investigation is required to determine the role of lack-of-evidence candidates in cancer. 259
DriverPower applied to whole exome sequencing 260
To demonstrate the robustness of DriverPower, we applied DriverPower to two public whole-261 exome sequencing (WES) datasets ( Supplementary Fig. 15 ). Both WES datasets are processed 262 differently than the PCAWG data and contain samples not included in the PCAWG study. For liver 263 cancer, using models trained for Liver-HCC (N=314), DriverPower identified 14 coding drivers 264 from 364 TCGA-LIHC samples (53 shared with Liver-HCC). All but one driver candidates were 265 present within the CGC or PCAWG-consensus. For pancreatic adenocarcinoma, using models 266 trained for Panc-AdenoCA (N=232), DriverPower identified 6 coding drivers from 180 TCGA-267 PAAD samples (no shared samples with the PCAWG study) and all corresponded to known driver 268 genes. 269
Discussion
270
Computational driver discovery is essential to distinguish driver from passenger mutations in 271 the coding and non-coding regions of whole cancer genomes. Here we report DriverPower, a 272 new framework for accurately identifying both types of driver mutation by combining mutational 273 burden and functional impact information. The method takes advantage of the large somatic 274 mutation sets produced by WGS technology to build an accurate global BMR model from more 275 than a thousand genomic features. This contrasts with methods that build a local BMR model 276 using selected or flanking regions. One advantage of this is that the method is not biased towards 277
coding regions, but uses the same model for coding and non-coding cancer driver discovery.
278
Another advantage is the method's high degree of modularity. DriverPower can potentially work 279
with any types of genomic element (contiguous or disjoint, coding or non-coding, proximate or 280 distal to genes), any regression algorithms for modelling BMR and any functional impact score 281 scheme. Although DriverPower is designed for WGS projects, it performs robustly in whole-exome 282 sequencing strategies as well. 283
In comparison to the other driver discovery methods evaluated by the PCAWG Drivers and Func-284
tional Interpretation Group, DriverPower provides the best balance of precision and recall, al-285
though is not always the top ranked method when either metric is considered independently ( Fig.  286 2b,d). As discussed in Supplementary Note 1, DriverPower is parameterized to allow for ad-287 justment of the precision-recall trade-off; in this study, we selected conservative parameters that 288 prioritize precision over recall especially for non-coding regions. 289
There are several ways in which the accuracy of DriverPower could be improved. One approach to 290 improve recall is to take into the account the potential presence of negative (purifying) selection 291
in the functional regions selected for testing. When the BMR model is trained, we use random 292 genomic elements that are predominantly under neutral selection. However, the functional ele-293 ments selected for testing are more likely to be under positive and/or negative selection 56 . The 294
observed mutation rate reflects the balance between positive and negative selection, and negative 295 selection at one site in the element will diminish the signal of positive selection at other sites, 296
reducing the sensitivity of the method as a whole. To our knowledge, no driver discovery tool 297
currently models the effect of negatively selected sites; future work aims to take this mechanism 298
into account. 299
The precision of the method can also be improved. False positive driver calls may be caused by 300
technical errors such as variant-calling artefacts that artificially increase the local mutation rate, 301
or by biological processes that are not captured by the BMR model such as regional differences 302
in activation-induced cytidine deaminase (AID) activity. These can potentially be mitigated by 303
incorporating into the BMR model additional features relevant to the technical and biological 304
processes. For example, incorporating read-level coverage, mapping and bias scores into the 305 BMR could help correct for regions prone to variant-calling artefacts, while features like the 306 number of palindrome loops and the fraction of mutations caused by AID per element could be 307 used to adjust for locally-acting hypermutation processes. 308
When applied to the PCAWG data set, DriverPower called nearly twice as many non-coding 309 driver events than coding ones, a ratio also observed by the PCAWG driver study. While this 310
unbalanced ratio may reflect cancer biology, there is also the possibility that it reflects, at least 311 in part, the technical challenge of sequencing and interpreting non-coding regions. Potential 312
artefacts include systematic undercalling of somatic variants in non-coding regions 24 , a problem 313 that could be rectified by deeper coverage. Another technical issue is raised by the fact that several 314
non-coding candidates are only significant in the pan-cancer cohort, suggesting that the data set 315 is statistically underpowered. To overcome this issue, we could either sequence more genomes 316
or reduce the size of the set of test elements by narrowing it to functional motifs or conserved 317 bases 57 . Lastly, functional impact score schemes are currently biased toward coding mutations; 318 therefore, improved functional scoring schemes will also help us identify more functionally relevant 319 non-coding cancer drivers in the future. 320
A comprehensive catalogue of coding and non-coding cancer drivers will accelerate the clinical 321 translation of cancer genomic study to precision medicine. As more cancer genomes and more 322 cancer types are sequenced, a general and accurate framework for computational driver discovery 323 like DriverPower will become increasingly useful. 324
Methods
327
Generation of cancer whole-genome somatic mutations. All DNA somatic single nucleotide 328 variations (SNVs) and indels for 2,583 donors were obtained from the PCAWG project (somatic 329 variant callset released October 2016) 9 . For our analysis, donors with hypermutated signatures 330
were excluded (n=69, defined as more than 30 mutations per Mb). Otherwise, we used the 331 same type-specific (n=29) and pan-cancer (all tumour samples except Skin-Melanoma, Lymph-332 NOS, Lymph-CLL and Lymph-BNHL) sample cohorts as the PCAWG Drivers and Functional 333
Interpretation Group (PDFIG; Supplementary Table 1 ). 334
Generation of simulated somatic mutations. We used three simulated datasets (Broad, 335
DKFZ and Sanger simulations) from the PDFIG (described in detail at ref. xx). These simulations 336
were made to capture the variation of background mutation rate and remove the signal of positive 337 selection through permutations of observed somatic mutations. 338
Generation of test and training genomic elements. We define a genomic element as the 339 collection of genome coordinates that defines one specific functional region of interest. For 340 example, the CDS element of TP53 is the combination of all protein coding regions in TP53. 341
We used eight test element sets in our analysis, including the CDS (n=20,185), splice site 342 (n=18,729), 5'UTR (n=19,369), 3'UTR (n=19,188), promoter (n=20,164), enhancer (n=30,816), 343
lncRNA (n=5,580) and lncRNA promoter (n=5,373). All test element sets were obtained from 344 the PCAWG project. GENCODE v19 was used as the reference gene model when building those 345 sets 58 . Non-coding RNA annotations were collected from multiple sources as described. 346
We constructed genomic element training sets by randomly sampling genome coordinates from 347 hg19, the build used for PCAWG. 2. Build the background mutation rate model using the gradient boosting machine, or random-366 ized lasso followed by binomial generalized linear models. The purpose of the BMR model 367
is to estimate the expected number of mutations (ŷ) for any genomic element. Namely, we 368 want to obtainŷ i = E(y i |X i , L i ) where X i and L i are the feature vector and length for 369 the element i. 370
3. Conduct burden test with observed (y) and predicted (ŷ) mutation counts, and perform 371 multiple testing correction. 372
4. Adjust observed mutation counts (y) based on functional impact scores for nearly significant 373 elements (q<0.25). 374
5. Re-assess the significance for nearly significant elements with functional adjusted mutation 375 counts followed by multiple testing correction. 376
Scaling of features. Features were scaled with RobustScaler from scikit-learn (version 0.18) 61 . 377
Feature scaling was only conducted for randomized lasso and GLMs. 378
Definition of excluded regions. In this study, all bases in the excluded regions were removed 379 before any analysis. The excluded region consists of three sets: (1) Feature selection with randomized lasso. To select features, we randomly sub-sampled 10% 388
of the training set 500 times. Then for the k-th subset with size N k , the following model was 389
fitted 63 : 390ŵ
where N is the total number of donors in the dataset, X is the feature matrix, w is the weight 391 vector, α is the regularization parameter, and b i is the scaling factor. The regularization parame-392 ter α was determined by a 5-fold cross-validated lasso with 33% of the training data. For the k-th 393 sub-sampling, the i-th feature was selected ifŵ ki ≥ 0.001. The final feature importance score 394 was calculated as the fraction of times that a feature was selected. Only features with score > 395 0.5 were used in the GLM BMR model. 396
Prediction of the BMR with GLM. When using the generalized linear model, we modelled 397 the observed mutations in each genomic element with a binomial distribution, that is 398
where y is the observed mutation count andŷ is the estimated mutation count. We used the 399 binomial generalized linear model to obtainŷ with the logit link function, that is 400ŷ
where X select is the selected feature matrix and β is the regression coefficient vector. 401
Prediction of the BMR with GBM. We trained the gradient boosting machine with XGBoost 64 . 402
All features were used in model training. The negative Poisson log-likelihood was chosen as the 403 objective function and ln(N · L) of elements were used as offset (i.e., base margin in XGBoost (SNVs) scores were used. CADD indel scores were generated with the CADD web interface for 420 all observed indels in the PCAWG dataset. For splice site, CADD and DANN scores were used. 421
For non-coding elements, the CADD, DANN and LINSIGHT (SNVs and indels) score were used. 422
Then the following steps were used to calculate the functional impact score per genomic element. 423
Firstly, raw scores were retrieved for all observed mutations in the dataset. Secondly, all raw 424 scores were converted to phred-like scores by -10 log 10 (rank/N m ), where N m is the number of 425 observed mutations having scores. Thirdly, for each genomic element, its functional score S was 426 calculated as: 427
where N is the number of donors ands i is the average functional impact score for the ith donor. 428
Adjustment of the mutation count. To compensate for the unbalanced number of mutations 429 among samples, instead of using the mutation count per element directly we used the geometric 430 mean of mutation count and sample count. That is, we use the balanced count y b = √ y · n d 431 instead of y directly for significance test, where n d is the number of mutated donors. Based 432 on the motivation that not all mutations should be weighted the same, the balanced mutation 433 count y b was then adjusted for nearly significant elements (raw q-value < 0.25) by a functional 434
weight w, that is y f = w · y b , where y f is the functionally adjusted mutation count. For the 435 element j, the functional weight w j was calculated based on its functional score S j and a threshold 436 score S T : 437
The threshold score S T is controlled by a single parameter F between 0 and 1, and can be 438
interpreted as the fraction of functionally relevant variants among all observed variants. Parameter 439
tuning of F can be found at Supplementary Note 1. 440
Assessment of the element significance. For each element, we calculated P (y b ≥ŷ) as 441 the raw p-value and P (y f ≥ŷ) as the function-adapted p-value. Since over-dispersion has 442
been documented in burden based methods and can affect the driver discovery accuracy 22 , here 443
we performed a regression-based overdispersion test for each tumour cohort using the training 444 set 66 . Based on the result of the overdispersion test, we calculated the raw and function-adpated 445 p-values by following a binomial distribution or a negative binomial distribution: 446
where p and θ are the p-value and dispersion parameter estimated from the overdispersion test, 447
and s is the scaling factor for θ used to accommodate the discrepancy between test and training 448 set in terms of the dispersion level. We used s = 3 for lymphomas and s = 1 otherwise in this 449
analysis. 450
Multiple testing correction. In all cases, q-values were generated by the Benjamini-Hochberg 451 procedure 67 . We chose q<0.1 as the significant level and q<0.25 as the nearly-significant level. 452
For each element set, multiple testing correction was performed for each tumour cohort (cohort 453 q-value) and across all tumour cohorts (global q-value). Cohort q-values were used in functional 454 adjustment and global q-values were used to define the final driver list. 455
Generation of reference cancer drivers. Reference cancer drivers were used to benchmark 456 the performance of DriverPower. Three reference sets were used: (1) the COSMIC Cancer Gene 457
Census (v82, n=567); (2) the PCAWG consensus driver candidates (PCAWG-consensus; n=157 458 for coding and n=26 for non-coding); (3) the PCAWG raw integrated driver candidates (PCAWG-459 raw; n=193 for coding and n=79 for non-coding). PCAWG-consensus (q-value post-filtering < 460 0.1) is a set of highly confident non-coding drivers and subjected to multiple stringent filters 461 as described. PCAWG-raw (q-value pre-filtering < 0.1) is a superset of PCAWG-consensus and 462
includes non-coding drivers that were not subjected to the filtering process. PCAWG-raw driver 463
candidates that are mutated in fewer than three samples were removed in this analysis. For 464 promoter and 5'UTR candidates in the PCAWG consensus drivers, we reversed the filtering for 465
overlapping elements (i.e., one element is selected over the overlapping element based on prior 466 knowledge). For example, we kept both the promoter and the overlapping 5'UTR of WDR74 in 467 this analysis; in the PCAWG consensus set, the WDR74 promoter is preferentially selected over 468
its 5'UTR. 469
Benchmarking of DriverPower. We compared coding and non-coding driver candidates 470
called by DriverPower to driver candidates called by six other published driver detection tools 471
(ActiveDriverWGS 25 , ExInAtor 20 , LARVA 22 , MutSig 24 , ncdDetect 21 and oncodriveFML 23 ). Driver 472 calls for 26 single tumour cohorts (no Skin-Melanoma, Lymph-CLL and Lymph-BNHL) were re-473 trieved from the PCAWG driver group. For each method, we removed driver candidates that are 474 mutated in fewer than three samples. We used precision (TP/(TP+FP)), recall (TP/(TP+FN)) 475
and F1-score (2*Precision*Recall/(Precision+Recall)) as performance metrics. 476
For CDS, we used the CGC gene set as the gold standard. For each method, true positive genes 477
were defined as genes presented in the gold standard set and the precision was then calculated as 478 the fraction of true positive genes among all called genes. For recall, since we can't accurately 479
know the expected set of driver genes that should be called for each tumour cohort in the dataset, 480 a lower-bound approximation was used instead. The lower-bound approximation was estimated 481
by taking the union of all true positive genes identified by each method and the recall was then 482 calculated as the fraction of true positive genes called among the lower-bound approximation. 483
For gene splice sites, the same gold standard gene set and benchmark method as CDS were used. 484
Due to data availability, the comparison was only performed for ncdDetect, oncodriveFML and 485
DriverPower. 486
For promoters, enhancers, 3'UTRs and 5'UTRs, because the number of non-coding driver candi-487
dates is small, four element sets were benchmarked together. No data for ExInAtor is available 488 for this comparison. For each tumour cohort, true positive driver elements were defined as el-489 ements called by at least three methods. The calculation of precision, recall and F1-score was 490 then identical as for the CDS and splice site. 491
Somatic copy number and structural variations analysis. We used SCNA (including GIS-492 TIC2.0 results) and SV call sets released January 2017 68 . The copy number status (loss, neutral 493 or gain) of a region is classified based on the difference between the absolute copy number of the 494 region and the genome-wide ploidy of the donor. candidates called by DriverPower contained within three reference driver sets (CGC, PCAWG-525 consensus or PCAWG-raw). For each element type, the number of candidates is also shown 526 above the bar. 527 method that are contained within reference gene sets. The colored columns in (c) correspond to 536 different reference driver sets (color legend is the same as Fig. 1e ). (e) shows the number and 537 fraction of non-coding driver candidates called by each method that are also called by others. As noted in the Method section, a single parameter F (the functional score threshold) was 548 used to control the degree of functional adjustment in DriverPower. Functional scores used in 549
DriverPower were positively correlated with the functional impact of mutations within elements. 550
The parameter F controls the threshold score (S T = -10 log 10 F ) and must be within the interval 551 (0,1]. The parameter F is negatively correlated with S T . Genomic element with score S > S T 552 will be up-weighted; while element with score S < S T will be down-weighted. Since DriverPower 553
uses phred-scale scores, F can be interpreted as the proportion of functionally relevant variants 554 among all observed variants. For instance, F = 0.01 means S T = 20 so elements with functional 555 score S > 20 (i.e., rank top 1% in phred-like scale) will receive a functional weight >1 and 556 gain additional significance from functional impact information. Using larger F will result in 557 smaller S T , and more elements will obtain additional significance, we hence expect to obtain 558 more driver candidates. Empirically speaking, larger F will cause higher recall but lower precision 559
as illustrated in Supplementary Fig. 16 . 560
The choice of F is dependent on the score scheme in use and/or the element set and tumour 561 cohort in test. Here to avoid overfitting, we divided all 2583 donors into training donor set 562 (N=1,117) and test donor set (N=1,136) to choose F for four score schemes (CADD, DANN, 563 EIGEN and LINSIGHT) and three element types (CDS, splice site and other non-coding sites) 564
separately. For CDS and splice site, we used the COSMIC cancer gene census (CGC) as the gold 565 standard set for parameter tuning. For other non-coding sites, we used the PCAWG-raw as the 566 gold standard set for parameter tuning. Precisions were calculated as the fraction of hits in the 567 gold standard set and pseudo-recalls were calculated as the number of significant candidates with 568 functional adjustment in gold standard over the number of nearly-significant candidates without 569 functional adjustment in gold standard. This calculation of pseudo-recall measured the relative 570 performance of DriverPower to its personal best. We observed that optimal parameters for the 571 training donor set also worked in a similar way for the test donor set. Parameters learnt here were 572 used for driver discovery in this analysis. 573
Supplementary Note 2 Difference from the PCAWG freeze 574
The list of coding and non-coding drivers produced by this analysis (v1.0.0) differs slightly from 575
the DriverPower results included in the PDFIG data analysis freeze due to the following reasons: 576 1. Hypermutated samples were not removed for the PCAWG freeze. 577
2. Only the binomial test was used in the PCAWG freeze. 578
3. The BMR model used in the PCAWG freeze was randomized lasso followed by GLM and in 579 this analysis was gradient boosting machines. 580 4. Only CADD and EIGEN scores are used in the PCAWG freeze, and element p-value is the 581 minimal p-value generated from two scores. 582
The threshold scores used for CADD and EIGEN in the PCAWG freeze were cohort-specific. 583
Namely, 85%-95% percentile score of each tumour cohort was used as threshold. 584
Around 83% of candidates identified by v1.0.0 were also in PCAWG freeze (Supplementary 585 Fig. 17a,c) . For coding driver discovery, the current version has higher precision and lower 586 recall ( Supplementary Fig. 17b ). For non-coding driver discovery, four candidates are only 587 significant in the current version, including the promoter of lncRNA RMRP in Breast-AdenoCA 588
and Stomach-AdenoCA, as well as LEPROTL1 promoter in Bladder-TCC and TERT promoter 589
in CNS-Oligo ( Supplementary Fig. 17d ). In addition, the removal of hypermutated samples 590 and the incorporation of negative binomial test alleviated the inflation issue in melanomas and 591 lymphomas. 592
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